ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

ClinicalTrials.gov ID: NCT04746924

Public ClinicalTrials.gov record NCT04746924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT04746924
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
BeiGene
Industry
Enrollment
662 participants

Conditions and interventions

Interventions

  • Ociperlimab Drug
  • Pembrolizumab Drug
  • Placebo Drug
  • Tislelizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 7, 2021
Primary completion
May 29, 2025
Completion
Mar 30, 2026
Last update posted
Jun 23, 2025

2021 – 2026

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
Providence Medical Foundation St Jude Heritage Healthcare Fullerton California 92835
Valkyrie Clinical Trials Los Angeles California 90067
Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala Ocala Florida 34474
Advent Health Cancer Institute Orlando Florida 32804
Goshen Center For Cancer Care Goshen Indiana 46526
Baptist Health Lexington Lexington Kentucky 40503
University Medical Center New Orleans West Jefferson Medical Center New Orleans Louisiana 70112
Metro Minnesota Community Oncology Research Consortium (Mmcorc) Saint Paul Minnesota 55101
West Penn Hospital Pittsburgh Pennsylvania 15224

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 209 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04746924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 23, 2025 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04746924 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →